APO Research
Talk to an analyst

APO RESEARCH · REPORT

ERBB2 Antibody

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global ERBB2 Antibody Market Outlook and Growth Opportunities 2026

19 December 2025193 pages

Choose your research edition.

Industry ResearchERBB2 Antibody Industry Research Report 2026116 pages · $2,950 USDIndustry Growth & TrendsGlobal ERBB2 Antibody Industry Growth and Trends Forecast to 2032103 pages · $3,450 USDMarket StructureGlobal ERBB2 Antibody Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal ERBB2 Antibody Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal ERBB2 Antibody Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

The global ERBB2 Antibody market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for ERBB2 Antibody is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for ERBB2 Antibody is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for ERBB2 Antibody is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the ERBB2 Antibody market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the ERBB2 Antibody market include Abbiotec, Bio X Cell, Biorbyt, Boster Bio, Everest Biotech, FineTest, Hytest, OriGene Technologies and ProSci, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global ERBB2 Antibody market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of ERBB2 Antibody and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents ERBB2 Antibody revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global ERBB2 Antibody market.

ERBB2 Antibody Segment by Company

Abbiotec

Bio X Cell

Biorbyt

Boster Bio

Everest Biotech

FineTest

Hytest

OriGene Technologies

ProSci

Proteintech

Santa Cruz Biotechnology

Merck

Thermo Fisher Scientific

ERBB2 Antibody Segment by Type

Polyclonal

Monoclonal

ERBB2 Antibody Segment by Application

Immunohistochemistry Paraffin

Immunohistochemistry Frozen

Immunoprecipitation

Enzyme Linked Immunosorbent Assay

Others

ERBB2 Antibody Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Colombia

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global ERBB2 Antibody status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the ERBB2 Antibody key companies, revenue, market share, and recent developments.

3. To split the ERBB2 Antibody breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions ERBB2 Antibody market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify ERBB2 Antibody significant trends, drivers, influence factors in global and regions.

6. To analyze ERBB2 Antibody competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global ERBB2 Antibody market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of ERBB2 Antibody and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of ERBB2 Antibody.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global ERBB2 Antibody industry.

Chapter 3: Detailed analysis of ERBB2 Antibody company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of ERBB2 Antibody in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of ERBB2 Antibody in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. ERBB2 Antibody Industry Trends Table 2. ERBB2 Antibody Industry Drivers Table 3. ERBB2 Antibody Industry Opportunities and Challenges Table 4. ERBB2 Antibody Industry Restraints Table 5. Global ERBB2 Antibody Revenue by Company (US$ Million) & (2021-2026) Table 6. Global ERBB2 Antibody Revenue Share by Company (2021-2026) Table 7. Global ERBB2 Antibody Company Ranking, (2024-2026) & (US$ Million) Table 8. Global ERBB2 Antibody Key Company Manufacturing Base & Headquarters Table 9. Global ERBB2 Antibody Company, Product Type & Application Table 10. Global ERBB2 Antibody Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global ERBB2 Antibody by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Polyclonal Table 15. Significant Companies of Monoclonal Table 16. Global ERBB2 Antibody Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global ERBB2 Antibody Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global ERBB2 Antibody Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global ERBB2 Antibody Sales Value Share by Type (2021-2026) Table 20. Global ERBB2 Antibody Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Immunohistochemistry Paraffin Table 22. Significant Companies of Immunohistochemistry Frozen Table 23. Significant Companies of Immunoprecipitation Table 24. Significant Companies of Enzyme Linked Immunosorbent Assay Table 25. Significant Companies of Others Table 26. Global ERBB2 Antibody Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global ERBB2 Antibody Sales Value by Application (2021-2026) & (US$ Million) Table 28. Global ERBB2 Antibody Sales Value by Application (2027-2032) & (US$ Million) Table 29. Global ERBB2 Antibody Sales Value Share by Application (2021-2026) Table 30. Global ERBB2 Antibody Sales Value Share by Application (2027-2032) Table 31. Global ERBB2 Antibody Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global ERBB2 Antibody Sales Value by Region (2021-2026) & (US$ Million) Table 33. Global ERBB2 Antibody Sales Value Share by Region (2021-2026) Table 34. Global ERBB2 Antibody Sales Value by Region (2027-2032) & (US$ Million) Table 35. Global ERBB2 Antibody Sales Value Share by Region (2027-2032) Table 36. Global ERBB2 Antibody Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global ERBB2 Antibody Sales Value by Country (2021-2026) & (US$ Million) Table 38. Global ERBB2 Antibody Sales Value Market Share by Country (2021-2026) Table 39. Global ERBB2 Antibody Sales Value by Country (2027-2032) & (US$ Million) Table 40. Global ERBB2 Antibody Sales Value Market Share by Country (2027-2032) Table 41. Abbiotec Company Information Table 42. Abbiotec Business Overview Table 43. Abbiotec ERBB2 Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 44. Abbiotec ERBB2 Antibody Product Portfolio Table 45. Abbiotec Recent Development Table 46. Bio X Cell Company Information Table 47. Bio X Cell Business Overview Table 48. Bio X Cell ERBB2 Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 49. Bio X Cell ERBB2 Antibody Product Portfolio Table 50. Bio X Cell Recent Development Table 51. Biorbyt Company Information Table 52. Biorbyt Business Overview Table 53. Biorbyt ERBB2 Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 54. Biorbyt ERBB2 Antibody Product Portfolio Table 55. Biorbyt Recent Development Table 56. Boster Bio Company Information Table 57. Boster Bio Business Overview Table 58. Boster Bio ERBB2 Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 59. Boster Bio ERBB2 Antibody Product Portfolio Table 60. Boster Bio Recent Development Table 61. Everest Biotech Company Information Table 62. Everest Biotech Business Overview Table 63. Everest Biotech ERBB2 Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 64. Everest Biotech ERBB2 Antibody Product Portfolio Table 65. Everest Biotech Recent Development Table 66. FineTest Company Information Table 67. FineTest Business Overview Table 68. FineTest ERBB2 Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 69. FineTest ERBB2 Antibody Product Portfolio Table 70. FineTest Recent Development Table 71. Hytest Company Information Table 72. Hytest Business Overview Table 73. Hytest ERBB2 Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 74. Hytest ERBB2 Antibody Product Portfolio Table 75. Hytest Recent Development Table 76. OriGene Technologies Company Information Table 77. OriGene Technologies Business Overview Table 78. OriGene Technologies ERBB2 Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 79. OriGene Technologies ERBB2 Antibody Product Portfolio Table 80. OriGene Technologies Recent Development Table 81. ProSci Company Information Table 82. ProSci Business Overview Table 83. ProSci ERBB2 Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 84. ProSci ERBB2 Antibody Product Portfolio Table 85. ProSci Recent Development Table 86. Proteintech Company Information Table 87. Proteintech Business Overview Table 88. Proteintech ERBB2 Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 89. Proteintech ERBB2 Antibody Product Portfolio Table 90. Proteintech Recent Development Table 91. Santa Cruz Biotechnology Company Information Table 92. Santa Cruz Biotechnology Business Overview Table 93. Santa Cruz Biotechnology ERBB2 Antibody Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 94. Santa Cruz Biotechnology ERBB2 Antibody Product Portfolio Table 95. Santa Cruz Biotechnology Recent Development Table 96. Merck Company Information Table 97. Merck Business Overview Table 98. Merck ERBB2 Antibody Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 99. Merck ERBB2 Antibody Product Portfolio Table 100. Merck Recent Development Table 101. Thermo Fisher Scientific Company Information Table 102. Thermo Fisher Scientific Business Overview Table 103. Thermo Fisher Scientific ERBB2 Antibody Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 104. Thermo Fisher Scientific ERBB2 Antibody Product Portfolio Table 105. Thermo Fisher Scientific Recent Development Table 106. Research Programs/Design for This Report Table 107. Authors List of This Report Table 108. Secondary Sources Table 109. Primary Sources List of Figures Figure 1. ERBB2 Antibody Product Image Figure 2. Global ERBB2 Antibody Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global ERBB2 Antibody Market Size (2021-2032) & (US$ Million) Figure 4. Global ERBB2 Antibody Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Polyclonal Image Figure 8. Monoclonal Image Figure 9. Global ERBB2 Antibody Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global ERBB2 Antibody Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global ERBB2 Antibody Sales Value Share by Type (2021-2032) Figure 12. Immunohistochemistry Paraffin Image Figure 13. Immunohistochemistry Frozen Image Figure 14. Immunoprecipitation Image Figure 15. Enzyme Linked Immunosorbent Assay Image Figure 16. Others Image Figure 17. Global ERBB2 Antibody Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global ERBB2 Antibody Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global ERBB2 Antibody Sales Value Share by Application (2021-2032) Figure 20. Global ERBB2 Antibody Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 21. Global ERBB2 Antibody Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 22. North America ERBB2 Antibody Sales Value (2021-2032) & (US$ Million) Figure 23. North America ERBB2 Antibody Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Europe ERBB2 Antibody Sales Value (2021-2032) & (US$ Million) Figure 25. Europe ERBB2 Antibody Sales Value Share by Country (%), 2025 VS 2032 Figure 26. Asia-Pacific ERBB2 Antibody Sales Value (2021-2032) & (US$ Million) Figure 27. Asia-Pacific ERBB2 Antibody Sales Value Share by Country (%), 2025 VS 2032 Figure 28. South America ERBB2 Antibody Sales Value (2021-2032) & (US$ Million) Figure 29. South America ERBB2 Antibody Sales Value Share by Country (%), 2025 VS 2032 Figure 30. Middle East & Africa ERBB2 Antibody Sales Value (2021-2032) & (US$ Million) Figure 31. Middle East & Africa ERBB2 Antibody Sales Value Share by Country (%), 2025 VS 2032 Figure 32. USA ERBB2 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 33. USA ERBB2 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 34. USA ERBB2 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 35. Canada ERBB2 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 36. Canada ERBB2 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 37. Canada ERBB2 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 38. Mexico ERBB2 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 39. Mexico ERBB2 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 40. Mexico ERBB2 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 41. Germany ERBB2 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. Germany ERBB2 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. Germany ERBB2 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. France ERBB2 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. France ERBB2 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. France ERBB2 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. U.K. ERBB2 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. U.K. ERBB2 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. U.K. ERBB2 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Italy ERBB2 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Italy ERBB2 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Italy ERBB2 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Spain ERBB2 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Spain ERBB2 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Spain ERBB2 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Russia ERBB2 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Russia ERBB2 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Russia ERBB2 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Netherlands ERBB2 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Netherlands ERBB2 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Netherlands ERBB2 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Nordic Countries ERBB2 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Nordic Countries ERBB2 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Nordic Countries ERBB2 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. China ERBB2 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. China ERBB2 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. China ERBB2 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Japan ERBB2 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Japan ERBB2 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Japan ERBB2 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. South Korea ERBB2 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. South Korea ERBB2 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. South Korea ERBB2 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. India ERBB2 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. India ERBB2 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. India ERBB2 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Australia ERBB2 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Australia ERBB2 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Australia ERBB2 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Southeast Asia ERBB2 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Southeast Asia ERBB2 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Southeast Asia ERBB2 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Brazil ERBB2 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Brazil ERBB2 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Brazil ERBB2 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Argentina ERBB2 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Argentina ERBB2 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Argentina ERBB2 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Chile ERBB2 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Chile ERBB2 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Chile ERBB2 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Colombia ERBB2 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Colombia ERBB2 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Colombia ERBB2 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Peru ERBB2 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Peru ERBB2 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Peru ERBB2 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Saudi Arabia ERBB2 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Saudi Arabia ERBB2 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Saudi Arabia ERBB2 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Israel ERBB2 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Israel ERBB2 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Israel ERBB2 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. UAE ERBB2 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. UAE ERBB2 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. UAE ERBB2 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Turkey ERBB2 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Turkey ERBB2 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Turkey ERBB2 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Iran ERBB2 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Iran ERBB2 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Iran ERBB2 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Egypt ERBB2 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Egypt ERBB2 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Egypt ERBB2 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Years Considered Figure 117. Research Process Figure 118. Key Executives Interviewed

Scope & coverage.

Types
  • Polyclonal
  • Monoclonal
Applications
  • Immunohistochemistry Paraffin
  • Immunohistochemistry Frozen
  • Immunoprecipitation
  • Enzyme Linked Immunosorbent Assay
  • Others
Companies covered
  • Abbiotec
  • Bio X Cell
  • Biorbyt
  • Boster Bio
  • Everest Biotech
  • FineTest
  • Hytest
  • OriGene Technologies
  • ProSci
  • Proteintech
  • Santa Cruz Biotechnology
  • Merck
  • Thermo Fisher Scientific

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global ERBB2 Antibody Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global ERBB2 Antibody Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 ERBB2 Antibody Market Dynamics
  1. 2.1 ERBB2 Antibody Industry Trends
  2. 2.2 ERBB2 Antibody Industry Drivers
  3. 2.3 ERBB2 Antibody Industry Opportunities and Challenges
  4. 2.4 ERBB2 Antibody Industry Restraints
3 ERBB2 Antibody Market by Company
  1. 3.1 Global ERBB2 Antibody Company Revenue Ranking in 2025
  2. 3.2 Global ERBB2 Antibody Revenue by Company (2021-2026)
  3. 3.3 Global ERBB2 Antibody Company Ranking (2024-2026)
  4. 3.4 Global ERBB2 Antibody Company Manufacturing Base and Headquarters
  5. 3.5 Global ERBB2 Antibody Company Product Type and Application
  6. 3.6 Global ERBB2 Antibody Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global ERBB2 Antibody Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 ERBB2 Antibody Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 ERBB2 Antibody Market by Type
  1. 4.1 ERBB2 Antibody Type Introduction
  2. 4.1.1 Polyclonal
  3. 4.1.2 Monoclonal
  4. 4.2 Global ERBB2 Antibody Sales Value by Type
  5. 4.2.1 Global ERBB2 Antibody Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global ERBB2 Antibody Sales Value by Type (2021-2032)
  7. 4.2.3 Global ERBB2 Antibody Sales Value Share by Type (2021-2032)
5 ERBB2 Antibody Market by Application
  1. 5.1 ERBB2 Antibody Application Introduction
  2. 5.1.1 Immunohistochemistry Paraffin
  3. 5.1.2 Immunohistochemistry Frozen
  4. 5.1.3 Immunoprecipitation
  5. 5.1.4 Enzyme Linked Immunosorbent Assay
  6. 5.1.5 Others
  7. 5.2 Global ERBB2 Antibody Sales Value by Application
  8. 5.2.1 Global ERBB2 Antibody Sales Value by Application (2021 VS 2025 VS 2032)
  9. 5.2.2 Global ERBB2 Antibody Sales Value by Application (2021-2032)
  10. 5.2.3 Global ERBB2 Antibody Sales Value Share by Application (2021-2032)
6 ERBB2 Antibody Regional Value Analysis
  1. 6.1 Global ERBB2 Antibody Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global ERBB2 Antibody Sales Value by Region (2021-2032)
  3. 6.2.1 Global ERBB2 Antibody Sales Value by Region: 2021-2026
  4. 6.2.2 Global ERBB2 Antibody Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America ERBB2 Antibody Sales Value (2021-2032)
  7. 6.3.2 North America ERBB2 Antibody Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe ERBB2 Antibody Sales Value (2021-2032)
  10. 6.4.2 Europe ERBB2 Antibody Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific ERBB2 Antibody Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific ERBB2 Antibody Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America ERBB2 Antibody Sales Value (2021-2032)
  16. 6.6.2 South America ERBB2 Antibody Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa ERBB2 Antibody Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa ERBB2 Antibody Sales Value Share by Country, 2025 VS 2032
7 ERBB2 Antibody Country-level Value Analysis
  1. 7.1 Global ERBB2 Antibody Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global ERBB2 Antibody Sales Value by Country (2021-2032)
  3. 7.2.1 Global ERBB2 Antibody Sales Value by Country (2021-2026)
  4. 7.2.2 Global ERBB2 Antibody Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA ERBB2 Antibody Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA ERBB2 Antibody Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA ERBB2 Antibody Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada ERBB2 Antibody Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada ERBB2 Antibody Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada ERBB2 Antibody Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico ERBB2 Antibody Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico ERBB2 Antibody Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico ERBB2 Antibody Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany ERBB2 Antibody Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany ERBB2 Antibody Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany ERBB2 Antibody Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France ERBB2 Antibody Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France ERBB2 Antibody Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France ERBB2 Antibody Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. ERBB2 Antibody Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. ERBB2 Antibody Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. ERBB2 Antibody Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy ERBB2 Antibody Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy ERBB2 Antibody Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy ERBB2 Antibody Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain ERBB2 Antibody Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain ERBB2 Antibody Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain ERBB2 Antibody Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia ERBB2 Antibody Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia ERBB2 Antibody Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia ERBB2 Antibody Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands ERBB2 Antibody Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands ERBB2 Antibody Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands ERBB2 Antibody Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries ERBB2 Antibody Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries ERBB2 Antibody Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries ERBB2 Antibody Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China ERBB2 Antibody Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China ERBB2 Antibody Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China ERBB2 Antibody Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan ERBB2 Antibody Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan ERBB2 Antibody Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan ERBB2 Antibody Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea ERBB2 Antibody Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea ERBB2 Antibody Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea ERBB2 Antibody Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India ERBB2 Antibody Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India ERBB2 Antibody Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India ERBB2 Antibody Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia ERBB2 Antibody Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia ERBB2 Antibody Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia ERBB2 Antibody Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia ERBB2 Antibody Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia ERBB2 Antibody Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia ERBB2 Antibody Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil ERBB2 Antibody Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil ERBB2 Antibody Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil ERBB2 Antibody Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina ERBB2 Antibody Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina ERBB2 Antibody Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina ERBB2 Antibody Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile ERBB2 Antibody Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile ERBB2 Antibody Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile ERBB2 Antibody Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia ERBB2 Antibody Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia ERBB2 Antibody Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia ERBB2 Antibody Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru ERBB2 Antibody Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru ERBB2 Antibody Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru ERBB2 Antibody Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia ERBB2 Antibody Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia ERBB2 Antibody Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia ERBB2 Antibody Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel ERBB2 Antibody Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel ERBB2 Antibody Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel ERBB2 Antibody Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE ERBB2 Antibody Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE ERBB2 Antibody Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE ERBB2 Antibody Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey ERBB2 Antibody Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey ERBB2 Antibody Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey ERBB2 Antibody Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran ERBB2 Antibody Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran ERBB2 Antibody Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran ERBB2 Antibody Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt ERBB2 Antibody Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt ERBB2 Antibody Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt ERBB2 Antibody Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Abbiotec
  2. 8.1.1 Abbiotec Company Information
  3. 8.1.2 Abbiotec Business Overview
  4. 8.1.3 Abbiotec ERBB2 Antibody Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Abbiotec ERBB2 Antibody Product Portfolio
  6. 8.1.5 Abbiotec Recent Developments
  7. 8.2 Bio X Cell
  8. 8.2.1 Bio X Cell Company Information
  9. 8.2.2 Bio X Cell Business Overview
  10. 8.2.3 Bio X Cell ERBB2 Antibody Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Bio X Cell ERBB2 Antibody Product Portfolio
  12. 8.2.5 Bio X Cell Recent Developments
  13. 8.3 Biorbyt
  14. 8.3.1 Biorbyt Company Information
  15. 8.3.2 Biorbyt Business Overview
  16. 8.3.3 Biorbyt ERBB2 Antibody Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Biorbyt ERBB2 Antibody Product Portfolio
  18. 8.3.5 Biorbyt Recent Developments
  19. 8.4 Boster Bio
  20. 8.4.1 Boster Bio Company Information
  21. 8.4.2 Boster Bio Business Overview
  22. 8.4.3 Boster Bio ERBB2 Antibody Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Boster Bio ERBB2 Antibody Product Portfolio
  24. 8.4.5 Boster Bio Recent Developments
  25. 8.5 Everest Biotech
  26. 8.5.1 Everest Biotech Company Information
  27. 8.5.2 Everest Biotech Business Overview
  28. 8.5.3 Everest Biotech ERBB2 Antibody Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Everest Biotech ERBB2 Antibody Product Portfolio
  30. 8.5.5 Everest Biotech Recent Developments
  31. 8.6 FineTest
  32. 8.6.1 FineTest Company Information
  33. 8.6.2 FineTest Business Overview
  34. 8.6.3 FineTest ERBB2 Antibody Revenue and Gross Margin (2021-2026)
  35. 8.6.4 FineTest ERBB2 Antibody Product Portfolio
  36. 8.6.5 FineTest Recent Developments
  37. 8.7 Hytest
  38. 8.7.1 Hytest Company Information
  39. 8.7.2 Hytest Business Overview
  40. 8.7.3 Hytest ERBB2 Antibody Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Hytest ERBB2 Antibody Product Portfolio
  42. 8.7.5 Hytest Recent Developments
  43. 8.8 OriGene Technologies
  44. 8.8.1 OriGene Technologies Company Information
  45. 8.8.2 OriGene Technologies Business Overview
  46. 8.8.3 OriGene Technologies ERBB2 Antibody Revenue and Gross Margin (2021-2026)
  47. 8.8.4 OriGene Technologies ERBB2 Antibody Product Portfolio
  48. 8.8.5 OriGene Technologies Recent Developments
  49. 8.9 ProSci
  50. 8.9.1 ProSci Company Information
  51. 8.9.2 ProSci Business Overview
  52. 8.9.3 ProSci ERBB2 Antibody Revenue and Gross Margin (2021-2026)
  53. 8.9.4 ProSci ERBB2 Antibody Product Portfolio
  54. 8.9.5 ProSci Recent Developments
  55. 8.10 Proteintech
  56. 8.10.1 Proteintech Company Information
  57. 8.10.2 Proteintech Business Overview
  58. 8.10.3 Proteintech ERBB2 Antibody Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Proteintech ERBB2 Antibody Product Portfolio
  60. 8.10.5 Proteintech Recent Developments
  61. 8.11 Santa Cruz Biotechnology
  62. 8.11.1 Santa Cruz Biotechnology Company Information
  63. 8.11.2 Santa Cruz Biotechnology Business Overview
  64. 8.11.3 Santa Cruz Biotechnology ERBB2 Antibody Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Santa Cruz Biotechnology ERBB2 Antibody Product Portfolio
  66. 8.11.5 Santa Cruz Biotechnology Recent Developments
  67. 8.12 Merck
  68. 8.12.1 Merck Company Information
  69. 8.12.2 Merck Business Overview
  70. 8.12.3 Merck ERBB2 Antibody Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Merck ERBB2 Antibody Product Portfolio
  72. 8.12.5 Merck Recent Developments
  73. 8.13 Thermo Fisher Scientific
  74. 8.13.1 Thermo Fisher Scientific Company Information
  75. 8.13.2 Thermo Fisher Scientific Business Overview
  76. 8.13.3 Thermo Fisher Scientific ERBB2 Antibody Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Thermo Fisher Scientific ERBB2 Antibody Product Portfolio
  78. 8.13.5 Thermo Fisher Scientific Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst